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Abstract
Imiquimod is a synthetic Toll-like receptor 7 (TLR7) agonist approved for the topical treatment of 
actinic keratoses, superficial basal cell carcinoma, and genital warts. Imiquimod leads to an 80–
100% cure rate of lentigo maligna, but studies of invasive melanoma are lacking. We conducted a 
pilot study to characterize the local, regional, and systemic immune responses induced by 
imiquimod in patients with high-risk melanoma. After treatment of the primary melanoma biopsy 
site with placebo or imiquimod cream, we measured immune responses in the treated skin, 
sentinel lymph nodes (SLN), and peripheral blood. Treatment of primary melanomas with 5% 
imiquimod cream was associated with an increase in both CD4+ and CD8+ T cells in the skin, and 
CD4+ T cells in the SLN. Most of the CD8+ T cells in the skin were CD25 negative. We could not 
detect any increases in CD8+ T cells specifically recognizing HLA-A*0201-restricted melanoma 
epitopes in the peripheral blood. The findings from this small pilot study demonstrate that topical 
imiquimod treatment results in enhanced local and regional T cell numbers in both the skin and 
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SLN. Further research into TLR7 immunomodulating pathways as a basis for effective 
immunotherapy against melanoma in conjunction with surgery is warranted.
INTRODUCTION
Invasive melanoma accounts for 4% of skin cancers, but causes approximately 71% of skin 
cancer deaths, largely due to aggressive metastatic disease. Primary melanomas can induce 
immune suppression in the sentinel draining lymph node (SLN) (Lee et al., 2005;Shu et al., 
2006). Specifically, antigen presentation by dendritic cells (DCs) can be negatively impacted 
in the sentinel nodes, leading to deficient tumor-specific T cell induction and inefficient 
control of metastatic spread (Pinzon-Charry et al., 2005). Identification of 
immunomodulating agents to enhance immune responses may result in better systemic 
immunity and improved control of metastases. After a biopsy demonstrates an invasive 
melanoma with a Breslow thickness greater than 1 mm, the current standard of care is to 
immediately excise the melanoma with wide surgical margins and to biopsy the SLN. 
However, the use of immune stimulating agents before surgical removal of the primary 
melanoma and SLN biopsy may provide additional immunoprotective benefit to patients 
with thicker high-risk melanoma (Erickson and Miller, 2010).
Imiquimod is a topical immunomodulator that is FDA-approved for use in external genital 
warts, superficial basal cell carcinoma, and actinic keratosis (Gaspari et al., 2009). It 
belongs to the imidazoquinoline small molecule family of Toll-like receptor (TLR) agonists. 
TLRss are conserved receptors that are important in pathogen recognition as well as linking 
innate and acquired immunity (Takeda and Akira, 2004). Imiquimod modulates immune 
responses through activation of TLR7 (Hemmi et al., 2002) located on endosomal 
membranes of antigen presenting cells (APCs), including myeloid and plasmacytoid 
dendritic cells (pDCs), monocytes, and macrophages. TLR7 activation induces secretion of 
proinflammatory cytokines, predominantly IFN-α, IL-12, and TNFα (Stanley, 2002), and 
facilitates the maturation and migratory capabilities of DCs (Prins et al., 2006). These 
responses help to bridge innate and acquired immune responses, leading to CD4+ T helper 
type 1 cell induction, as well as cytotoxic CD8+ anti-tumor T cell responses. Persistent TLR 
signaling may also be required to bypass regulatory T cell-induced tolerance (Yang et al., 
2004). Previous studies have demonstrated that other TLR-stimulating agents, such as CpG 
oligodeoxynucleotide (TLR9 agonist), enhance DC responses in the SLNs of cancer patients 
(Molenkamp et al., 2007).
There have been few clinical studies to systematically evaluate neoadjuvant 
immunomodulators in primary melanoma patients undergoing surgical excision. Here we 
describe a pilot study of a two-week topical course of imiquimod cream or placebo applied 
to the primary melanoma site prior to surgical excision of tumor and SLN biopsy. Cellular 
immunological parameters in the skin and lymph nodes were evaluated following treatment. 
We hypothesized that treatment of primary cutaneous melanoma with imiquimod prior to 
surgery would lead to a program of inflammation at the tumor site and SLN that might 
enhance systemic anti-melanoma immunity. Because enhanced DC responses might lead to 
increased tumor antigen presentation and naïve T cell induction, we included in the study 
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measurements of melanoma antigen-specific T cell responses in the peripheral blood before 
and after therapy.
RESULTS
Patient selection and treatment
Fourteen patients with primary melanoma tumors measuring >1.0 mm Breslow thickness 
were enrolled in the study. Patients were randomly assigned to pre-operative topical 
administration of either 5% imiquimod cream or vehicle (placebo) cream to their tumor 
areas, every day for two weeks prior to surgical removal of tumor and sentinel lymph nodes. 
The final day of treatment was the day before surgery (day -1). Blood samples were 
obtained from each patient before and after treatment (day -14 and day 0). Tumor sites were 
examined and photographed on these days for comparison. One patient from each group did 
not complete the SLN resection for clinical reasons unrelated to this study, and these 
patients were not included in the SLN analysis.
No severe local or systemic adverse reactions were observed in any of the patients after two 
weeks of treatment. Signs of local inflammation, including erythema and edema, were 
expected to occur in some patients in the imiquimod-treated group. Four out of the six 
analyzable imiquimod-treated patients had clinical evidence of a pharmacologic response, 
i.e., obvious signs of local inflammation, including erythema, crusting, or scaling in the area 
of treatment. Two imiquimod-treated patients had no clinical evidence of a pharmacologic 
response, and displayed no visible differences in the skin pre- and post-treatment. The 
patient with the most overt, marked inflammatory response (Patient 2) had an obviously 
enlarged SLN (greater than 1 cm). However, despite having obvious visible tumor prior to 
treatment on day - 14 (Figure 1), melanoma cells could not be detected in the excised tumor 
area or SLN on day 0. In the placebo-treated group, only one patient developed mild 
erythema, while five others displayed no clinical differences between pre- and post-
treatment. On day 0, tumors and SLNs were surgically removed from all patients.
Local cutaneous effects of TLR7 activation
Based on prior reports, we hypothesized that topically applied imiquimod would lead to 
localized skin inflammation. After applying cream topically for two weeks, we evaluated 
patients' primary tumor sites for the infiltration of immune cells following imiquimod or 
placebo treatment. Paraffin-embedded serial sections were stained with antibodies to 
identify lymphocytes and monocyte/macrophage/dendritic lineage cells, and assessed by 
immunohistochemistry (IHC). Significantly higher levels of CD3+ T cells, both CD4+ and 
CD8+, were observed in the local skin regions of the primary tumor site following treatment 
with imiquimod, compared to placebo (Figure 2a). Subtype analysis of these cells revealed 
that most CD8+ cells were CD25- (separately submitted manuscript). During analysis of 
non-lymphocyte markers, conversely, we were unable to detect significant differences 
between imiquimod- and placebo-treated groups in levels of myeloid DCs (CD1a+ and 
CD11c+), macrophages (CD14+ and CD68+), antigen presenting cells (HLA-DR+, S100+), 
plasmacytoid DCs (CD123+), or Langerhans cells (Langerin+) (Figure 2b). Within the 
imiquimod-treated group, patients displaying the highest levels of most immune markers in 
Narayan et al. Page 3
J Invest Dermatol. Author manuscript; available in PMC 2012 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
the skin by IHC corresponded with the clinically visible responders. However, the study was 
not powered to permit further statistical analysis based on this clinical response 
classification within the imiquimod group.
Immunological effects of TLR7 activation in sentinel lymph node
Fresh SLN sections were obtained prior to histopathological analysis, and single-cell 
suspensions were prepared for flow cytometric quantitation of immune cell numbers. 
Antibody staining of lymph node cells was performed using a similar array of biomarkers as 
in the skin, but also included CD209 and CD83 for a subset of patients. As in the skin, 
imiquimod treatment induced increased percentages of CD3+ lymphocytes compared with 
placebo. The percentage of CD4+ cells was significantly higher and the percentage of CD8+ 
cells trended higher in the imiquimod group as well (Figure 3a).
We used both IHC and flow cytometry to quantitate the levels of monocyte/macrophage/
dendritic cell infiltration of the lymph nodes. Single stains with the antibodies used in Figure 
2 revealed no significant differences between placebo-treated and imiquimod-treated groups, 
as shown by IHC (Figure 3b). A subset of patients was assessed for additional monocyte 
lineage surface markers by flow cytometry. We were unable to detect significant differences 
in CD123+, CD123+CD11c− (defining a plasmacytoid DC subset), and CD209+ 
populations between placebo- and imiquimod-treated groups (Figure 3c). Double staining 
with CD83 allowed assessment of the activation status of these populations. These 
measurements also failed to detect differences in the numbers of activated CD1a+, CD11c+, 
and CD209+ populations between the two groups of patients (Figure 3d).
Assessment of melanoma-specific peripheral T cells before and after imiquimod treatment
Lymphocytes were purified from PBMCs harvested from patients before and after 
imiquimod (or placebo) treatment, and potential tumor specificity was assessed in the subset 
of HLA-A*0201-positive patients using tetramer staining assays. We chose defined HLA-
A*0201-binding epitopes derived from MART-1, tyrosinase, and gp100, as these represent 
commonly found T cell receptor specificities in melanoma patients (Comin-Anduix et al., 
2008). Following staining and flow cytometric analysis, CD8+ cells that stained positive 
with these tetramers were assessed. Slight increases in the percentage of tetramer+ cells 
were seen in some individuals following the two-week treatment period (Figure 4). 
However, in terms of overall number of responses observed, there were no significant 
differences between placebo- and imiquimod-treated groups for any of the three tumor-
antigen-specificities analyzed.
DISCUSSION
Imiquimod has shown clinical efficacy in a number of different skin neoplasms, including 
superficial basal cell carcinoma and actinic keratoses, but its exact mechanism of action is 
largely undefined. Imiquimod has been widely used off-label in cases of lentigo maligna 
(LM) and cutaneous metastatic melanoma (Naylor et al., 2003;Cotter et al., 2008;Buettiker 
et al., 2008;Powell et al., 2009). Additionally, others and we have demonstrated the ability 
of imiquimod to enhance vaccine-associated protection against melanoma in mice (Ma et 
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al., 2010;Craft et al., 2005;Prins et al., 2006). Although surgical excision is generally the 
main treatment modality for both LM and invasive melanoma, imiquimod has been used in 
patients with confounding co-morbidities which limit their surgical candidacy, and in 
patients with tumors in anatomic areas that would lead to aesthetic or functional 
impairments. Currently, only case studies have been reported on imiquimod as a 
monotherapy for cutaneous metastases of melanoma, although there has been a Phase I/II 
study of topical imiquimod combined with intralesional IL-2 that demonstrated some 
clinical responses in cutaneous metastases (Green et al., 2008). Topical imiquimod 
treatment can lead to 75% cure rates of melanoma in situ without surgery (Cotter et al., 
2008). However, overall data remains inconclusive, due to small study sizes and short 
follow-up periods (Rajpar and Marsden, 2006;Erickson and Miller, 2010). We hypothesized 
that topical imiquimod treatment of high-risk invasive primary melanoma in humans would 
lead to increased anti-tumor immune responses in the skin and SLN. In this pilot study, we 
identified, quantified, and compared local tumor site and draining lymph node immune 
responses in imiquimod- and placebo-treated primary malignant melanoma patients. Clinical 
outcomes associated with treatment were not the focus of this study.
Our data demonstrates that topical imiquimod treatment significantly elevates levels of 
CD4+ and CD8+ lymphocytes, both locally in the skin, and in the draining sentinel lymph 
nodes, as compared to patients treated with placebo. We were unable to detect, however, 
significant differences in the levels of DCs, macrophages, Langerhans cells, or other antigen 
presenting cells. The fact that this was a pilot study with small numbers of patients allowed 
only large differences between groups to be detected. Previous studies have shown evidence 
that topical imiquimod treatment is associated with local infiltration of both myeloid and 
lymphoid immune cells (DeGiorgi et al., 2009;Torres et al., 2007). Infiltration of T 
lymphocytes and DCs into superficial basal cell carcinomas (Barnetson et al., 2004) and 
actinic keratoses (Ooi et al., 2006) were associated with imiquimod treatment. We initially 
hypothesized that imiquimod-treated patients would have either increased numbers of 
monocyte lineage cells, or higher activation levels. Although we examined the activation 
marker CD83 and could not detect increased levels in the small number of imiquimod-
treated patients in this study, we did not examine potential functional differences, such as 
cytokine or chemokine expression, that might influence lymphocyte infiltration.
The predominant cell type that responds to TLR7 stimulation in humans is the plasmacytoid 
dendritic cell (pDC) (Gibson et al., 2002), identified in this study by CD123+CD11c− 
staining, although conventional myeloid DCs, identified as CD11c+, have also been shown 
to respond to TLR7 agonists (Ito et al., 2002). One major response of activated pDCs is the 
expression of type I IFNs (IFNαand IFNβ) via signaling through NFκB. Indeed, a 
microarray analysis of imiquimod treatment of superficial basal cell carcinomas and 
cutaneous T cell lymphomas revealed increased expression of IFNα-induced genes that 
correlated with higher numbers of tumor-infiltrating activated pDCs (Urosevic et al., 2005). 
Our data did not reveal significant differences in pDC populations in the SLN or the excised 
tumor; however, the previous study was performed only 5 days following initiation of 
imiquimod treatment, compared to 2 weeks in our study. In addition to pDCs, other cell 
types expressing TLR7 may also be involved in the inflammation observed in our study, and 
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in the clinical effect observed in the treatment of skin tumors here and in prior reports. These 
cells include myeloid DCs, T cells, B cells, and monocyte/macrophages. Although statistical 
significance was not reached due to the limited sample size, cells expressing the monocyte/
macrophage marker CD68 were detected in higher numbers in imiquimod-treated tumor 
sites than in skin treated with placebo cream. Cytokine release may also lead to indirect 
effects on other cell subpopulations, reflecting the complex inter-relationships among 
immune cells during imiquimod treatment.
Signs of localized visible inflammation are strong predictors of therapeutic benefit in LM 
patients treated with imiquimod (Powell et al., 2009). Among the imiquimod-treated 
patients in this study, varying degrees of clinical inflammation were evident following the 
two-week treatment course. Comparing post-treatment to pre-treatment, 4 out of 6 patients 
treated with imiquimod showed clinical inflammation—erythema, crusting, or scaling—
while two of six had no obvious visible changes after 14 days of treatment. Thus, because 
5% topical imiquimod was not always associated with obvious local changes, we 
characterized subsets within the treatment group as pharmacologic responders and non-
responders based on visible local inflammation of the skin. It is possible that genetically 
distinct subsets of the population respond differently to immunomodulation by imiquimod. 
Single nucleotide polymorphisms (SNPs) have been described for TLR7 and TLR8, 
including alleles that are associated with disease outcomes for HCV (Schott et al., 2008) and 
HIV infection (Oh et al., 2008), suggesting that genetic variation might potentially 
contribute to varied clinical responses to TLR ligand stimulation. Whatever the cause of 
variability in TLR ligand responses, larger future studies could be designed to account for 
individual patients having varying degrees of pharmacologic responses to imiquimod.
Recent evidence has implicated CD8+/CD25−/granzymeB+/perforin+ T cells as a 
population that is capable of responding immediately to immune stimulation (separately 
submitted manuscript). Activation and proliferation of T cells through the TCR normally 
leads to CD25 upregulation. The increased numbers of CD8+ T cells that we observed in 
treated skin and SLN sections of imiquimod-treated patients were found by co-staining to be 
CD25 negative (data in a separate manuscript under review). This observation suggests that 
these cells are likely infiltrating and proliferating in response to TLR7 stimulation in the 
absence of antigen.
In patient PBMCs, we were unable to detect any T cells that recognize epitopes from three 
common melanoma targets, MART-1, tyrosinase, and gp-100. Because imiquimod was 
applied to tumor sites before surgical excision, the tumor itself might serve as an antigen 
source for endogenous DCs that are activated by imiquimod. Any antigen-loaded DC could 
then traffic to the draining lymph nodes to activate tumor-specific T cells. The fact that no 
melanoma antigen-specific T cells could be detected in PBMCs from these melanoma 
patients does not rule out their existence, since the epitopes examined do not represent a 
complete array of potential targets that might be recognized by T cells. Additionally, any 
potentially generated antigen-specific T cells might be predicted to leave the circulation and 
home to the tumor, thus precluding their detection in the blood. Ultimately, larger studies 
with longer follow-up times are needed to determine the importance of CD8+/CD25− T 
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cells, or if imiquimod-induced infiltration of T cells into the skin and SLN leads to increased 
circulating melanoma antigen-specific T cells or clinical survival benefit.
Many clinicians and scientists hypothesize that immune-based therapies delivered before the 
SLNs are excised from patients with melanoma could result in improved systemic 
immunosurveillance for micrometastases. Because the risk of topical imiquimod use is 
exceedingly low, the results from this pilot study suggest a large-scale randomized, placebo 
controlled clinical trial may be warranted. The proposed trial would use imiquimod or other 
TLR agonists as topically-applied, pre-surgical neoadjuvants to determine if long-term, 
disease-free survival or overall survival is improved. Further characterization of the effector 
cells induced by imiquimod and the mechanisms involved in tumor clearance are also 
warranted.
MATERIALS AND METHODS
Study design, patients, and treatment schedule
This prospective pilot study was designed to determine the clinical variability of responses 
to topical imiquimod in patients with high risk primary melanoma, and was modeled after a 
previous sentinel lymph node analysis performed in melanoma patients (Vuylsteke et al., 
2004). Thus, although the study was not powered to detect differences in clinical outcomes, 
it was still designed as a randomized, double-blind, placebo-controlled study to model 
potential future applications. For this pilot, the target enrollment was n=6 in each group. 
Inclusion criteria were: 18 years of age and older, and diagnosis of primary melanoma with 
a pathological Breslow thickness greater than 1.0 millimeter. Exclusion criteria included: 
primary biopsy of the wide excisional type with depth-appropriate margins, location of the 
tumor on the head and neck, prior treatment with immunotherapy or chemotherapy, ongoing 
immunotherapy, prior diagnosis with autoimmune disorder, presence of co-morbid 
conditions precluding lymph node biopsy, evidence of any clinically evident metastases, and 
pregnancy and/or breastfeeding. All patients received the standard of care for high-risk 
melanoma including pre-surgical staging work-up, wide local excision of tumor, 
lymphoscintigraphy and SLN biopsy, and post-surgical care. Fourteen patients enrolled in 
the study after giving written, informed consents. Patients were randomized in a 1:1 ratio to 
receive imiquimod 5% cream (3M Pharmaceuticals, Saint Paul, MN and later Graceway 
Pharmaceuticals) or vehicle cream (3M Pharmaceuticals, Saint Paul, MN and later 
Graceway Pharmaceuticals). On day -14 before surgical excision, primary lesions were 
photographed and 100 mLs of blood were collected for pre-therapy immune monitoring 
studies and HLA typing. Starting on day -14, patients were instructed to apply the cream 
(250 mg) once daily over the affected area for 14 days. Patients were not advised to occlude 
the area. Patients were evaluated on day -7 and a second photograph of the tumor site was 
taken. On the day of surgery (day 0), a post-treatment photograph was taken and another 100 
mLs of blood were obtained for post-therapy immunoassays. Patients then underwent wide 
excision of the tumor and SLN biopsy using standard surgical techniques, and samples were 
processed for IHC, flow cytometry, and/or immunoassays as described below. This study 
was approved by the Institutional Review Board at the Los Angeles Biomedical Research 
Institute and the University of California Los Angeles (UCLA), and was conducted under 
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Good Clinical Practices guidelines at the Harbor-UCLA Medical Center and the UCLA 
Medical Center, as well as adherence to the declaration of Helsinki Guidelines.
Immunohistochemistry of Paraffin-embedded Tumor
Sections of excised tumors were placed in 10% formalin and processed as typically 
performed by the Pathology department. Serial sections from the paraffin-embedded blocks 
were subsequently obtained and evaluated for infiltration of immune cells using standard 
IHC procedures. Antibodies against CD3 (BD Biosciences), CD4 (US Biological), CD8 
(Ancell), CD14 (Novocastra), CD1a (US Biological), S100 (US Biological), Langerin (US 
Biological), CD68 (US Biological), CD83 (US Biological), CD86 (Abcam), CD11c 
(Abcam), CD123 (US Biological), and HLA-DR (US Biological) were used for staining. 
Image analysis of stained slides was performed by an observer blinded to the treatment 
assignment using the Image-Pro Plus software (Media Cybernetics, Silver Spring, MD). A 
compiled image of the region containing the tumor was taken for each slide (10×), and 
stained areas within the tumor were measured using the color segmentation function. For 
each interpretable slide, the observer measured percentages of positively stained area as a 
function of the total area of the epidermis or dermis containing the tumor.
Isolation of SLN cells
Sentinel lymph nodes were collected immediately after dissection and placed in sterile, ice-
cold medium. Nodes were bisected and viable cells were collected by removing a thin, 
cross-sectional slice of the interior of the node in a sterile manner. Tissue was incubated in 
complete medium [IMDM (Invitrogen), 10% human AB Serum (Cellgro), 50 IU/ml 
penicillin-streptomycin (Invitrogen), and 0.05 mmol/2-mercaptoethanol (Invitrogen)] 
containing 0.01% DNase I (Sigma) and 0.14% collagenase A (Roche) for 45 minutes, and 
subsequently macerated between frosted glass slides to obtain a single cell suspension. Cells 
were then washed with complete medium, counted, and processed for flow cytometry or 
IHC.
Flow Cytometry of SLN Cells
Isolated SLN cells were resuspended in IMDM supplemented with 10% human AB serum to 
block FcγIII/IIR (CD16/CD32). Cells were stained for the following markers obtained from 
BD Pharmingen (San Diego, CA): CD1a-FITC, CD3-FITC, CD4-PE, CD8-PE, CD11c-
PECy5, CD14-FITC, CD83-PE, CD86-PECy5, CD123-PE, and CD209-FITC. Matched 
isotype monoclonal antibodies served as negative controls. Subsequently, cells were 
analyzed by flow cytometry (FACSCalibur, BD Biosiences, Mountain View, CA) at 
100,000 events per measurement, and positive gates for each biomarker were defined.
Immunohistochemistry of SLN
Immunohistochemical analysis of immune cells in the SLN was performed as described 
above. IHC results are reported for each SLN as the percentage of the total nodal area 
positively stained for the specified marker. All slides were evaluated without knowledge of 
the SLN tumor status or treatment group.
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Blood Collection and cryopreservation
Patients underwent two peripheral blood collections of 100 mL whole blood: once prior to 
treatment initiation on study day -14, and once following treatment, on day 0. Blood samples 
from day -14 were sent to UCLA Genetics Laboratory for HLA-A*0201 typing. Peripheral 
blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque (GE Healthcare) 
centrifugation of whole blood. PBMCs were cryopreserved at a concentration of 1 × 107/mL 
in RPMI (Invitrogen) supplemented with 20% (v/v) heat-inactivated human AB serum 
(Cellgro) and 10% DMSO (Sigma) at −80°C, to allow for large batch processing on a single 
day.
Peptides and Tetramer Analysis
Tetramer analysis was performed on HLA-A*0201 positive patients, using the following 
HLA-A*0201-binding peptide epitopes: MART126–35 (ELAGIGILTV), tyrosinase368–376 
(YMDGTMSQV) and gp100209– 217 (ITDQVPFSV), representing three immunodominant 
tumor antigens, as well as negative control [(AFP)325–332 (GLSPNLNRFL)] and positive 
control [(CMV)pp65495–503 (NLVPMVATV)] epitopes. All tetramers were purchased from 
Beckman Coulter Inc., San Diego, CA, as peptide preloaded reagents, and the assay was 
performed as previously described (Comin-Anduix et al., 2006). Briefly, each patients’ 
PBMCs were thawed simultaneously and treated with DNase for one hour at 37°C. Then, 
1×106 cells were stained at room temperature for 30 minutes with each MHC tetramer, plus 
CD8-FITC (Caltag) and a CD4/CD13/CD19 antibody cocktail (Caltag) for gating. Cells 
were subsequently washed and analyzed immediately using a FACScan flow cytometer 
(Becton Dickinson). Lymphocytes were gated based on forward and side scatter, and those 
positive for CD4/CD13/CD19 were gated out. The percentages of CD8+ cells that stained 
with tetramer before and after treatment were measured and compared using a standardized 
gating algorithm. Results were analyzed based on the criteria previously defined (Comin-
Anduix et al., 2006).
Statistical Analysis
The stained area percentages and the flow cytometric data in the primary tumor and SLN 
studies were presumed to have normal distributions based on previous measurements. The 
mean and difference in the percentage of area (IHC) or cell number (flow cytometry) stained 
in the melanoma and lymph node tissue samples for imiquimod-treated versus placebo 
groups were compared using an unpaired two-tailed t-test. Pre- and post- treatment values of 
tetramer staining were analyzed using the Wilcoxon signed-rank test. P-values of <0.05 
were considered to be significant, and multiple comparison adjustments were not applied 
given the number and nature of the cell markers being analyzed. Changes in cell counts were 
summarized in 6 imiquimod-treated and 6 placebo patients with means and standard 
deviations, and with the group difference 95% confidence interval for the estimated 
treatment effect.
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Abbreviations used
APC antigen presenting cell
DC dendritic cell
IHC immunohistochemistry
LM lentigo maligna
MM metastatic melanoma
pDC plasmacytoid dendritic cell
SLN sentinel lymph node
TLR Toll-like receptor
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Figure 1. Melanoma site of "responder", pre- and post-treatment with imiquimod
Patient applied topical imiquimod to tumor site starting on day -14, and ending on day -1, 
before surgery on day 0.
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Figure 2. Immune biomarkers in local tumor sites
Skin sections from placebo-treated (closed circles) and imiquimod-treated (open squares) 
patients were assessed by IHC. Percent areas staining positive for lymphocyte markers (a) 
and monocyte/macrophage/dendritic cell lineage markers (b) were quantitated using Image 
Pro software. Means +/− SEM are shown, N=7 for all groups except CD8-imiquimod (6), 
HLA-DR-placebo (6), and HLA-DR-imiquimod (3). P values for CD3=0.01, CD4=0.03, 
CD8=0.01.
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Figure 3. Immune biomarkers in primary sentinel lymph nodes, by flow cytometry or IHC
Lymph node sections and single cell suspensions from placebo-treated (closed circles) and 
imiquimod-treated (open squares) patients were assessed by IHC and flow cytometry, 
respectively. Lymphocytes were quantitated by flow cytometry (a), monocyte/
macrophage/DC lineage cells were quantitated by IHC (b) or flow cytometry (c), and 
activation markers on monocyte/DC cells were quantitated by flow cytometry (d). Means +/
− SEM are shown, N=6 for all groups except in: (b) CD14-placebo (5), HLA-DR-placebo 
(5), and HLA-DR-imiquimod (2); (c) all subgroups were 4 or 3; (d) CD209/CD83 was 4 and 
3. P values in (a) for CD3=0.02, CD4=0.04, CD8=0.12.
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Figure 4. Tetramer staining of PBMC CD8+ lymphocytes following imiquimod or placebo 
treatment
Lymphocyte-enriched PBMC fractions from HLA-A*0201-positive patients (4 placebo-
treated, 5 imiquimod-treated) were assessed for recognition of HLA-A*0201-binding 
melanoma epitopes derived from MART-1, tyrosinase, or gp100, by tetramer staining. 
Differences between pre- and post-treatment were assessed per individual, and placebo- and 
imiquimod-treated group differences compared using the Wilcoxon signed-rank test.
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